Epstein-Barr virus latent membrane protein 1 peptide-MHC class I complex (LMP1-pMHC)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide epitopes presented on MHC class I molecules are primary targets for T-cell mediated immunotherapy in EBV-associated malignancies (PMID: 23414387). LMP1 is a potent viral oncogene that functions as a constitutively active mimic of the CD40 receptor, promoting cell survival and proliferation in B-cells and epithelial cells (UniProt P03230). While the full-length LMP1 protein is often poorly immunogenic or difficult to target with antibodies due to its transmembrane nature, its intracellular processing yields specific peptides, such as the HLA-A*02:01-restricted YLQQNWWTL, which are displayed by MHC class I molecules for surveillance by CD8+ T cells (PMID: 15140913). These peptide-MHC complexes serve as the fingerprint of EBV-infected cells, allowing for the development of highly specific therapies like TCR-engineered T cells (TCR-T) and EBV-specific cytotoxic T lymphocytes (CTLs) (PMID: 30552139). Such treatments are particularly relevant for diseases like nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorders (PTLD) where LMP1 is consistently expressed (PMID: 25406378). However, the effectiveness of targeting these epitopes is often limited by the downregulation of MHC molecules by tumor cells and the requirement for specific HLA matching between the therapy and the patient (PMID: 28243103).

Other names

EBV LMP1 peptide-HLA complexLMP1-derived MHC I epitopesLatent membrane protein 1 antigenic peptidesLMP1-pMHC

Recognition by T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, leading to targeted lysis of EBV-infected or transformed cells (PMID: 30552139).